Skip to content
Clinical Trials – home
SwedenBack to Sweden

Clinical trials in Helsingborg – page 47

1 322 clinical trials in Helsingborg, Sweden. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Helsingborg at a glance
1 322
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 322 trials in Helsingborg

Open in trial search

Dermatitis atopic

Not yet recruiting

Study on Rocatinlimab for Adolescents Aged 12-17 with Moderate-to-Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Malignant peritoneal neoplasm+1

Not yet recruiting

Maintenance therapy with raludotatug deruxtecan alone or with bevacizumab versus standard care in patients with newly diagnosed advanced ovarian cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Hypoparathyroidism

Not yet recruiting

Study of Encaleret Hemisulfate Hemihydrate for Efficacy, Safety and Tolerability in Adults with Chronic Hypoparathyroidism

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:Calcilytix Therapeutics Inc.

Schizophrenia

Not yet recruiting

A study to evaluate the effect of xanomeline tartrate and trospium chloride on cognitive impairment in adults with schizophrenia.

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Trospium Chloride
  • Sponsor:European Group for Research in Schizophrenia Stichting

Multiple sclerosis

Not yet recruiting

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Breast cancer+2

Not yet recruiting

Gedatolisib with drug combination versus standard therapy as first‑line treatment for patients with advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Celcuity Inc.

Hereditary ataxia+1

Not yet recruiting

Long‑term safety of intrathecal VO659 in participants with Huntington’s disease, spinocerebellar ataxia type 1 or type 3

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:VO659
  • Sponsor:Vico Therapeutics B.V.

Study of Tozorakimab to Reduce Lung Inflammation and Promote Healing in Patients with COPD

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Tozorakimab
  • Sponsor:University Of Leicester

Schizophrenia

Not yet recruiting

Phase 3 Double‑Blind Relapse Prevention Trial of Trospium Chloride and Xanomeline Tartrate (KarXT) in Adults with Schizophrenia

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Pancreatic carcinoma+2

Not yet recruiting

Molecularly Tailored Therapy Versus Standard Care in Patients With Advanced Pancreatic Cancer Using Olaparib, Erlotinib, Crizotinib, Trametinib, Pemigatinib, Selpercatinib, Axitinib, Vismodegib, Pembrolizumab, Larotrectinib, Dabrafenib, Capecitabine, Oxaliplatin, Fluorouracil, Irinotecan, Gemcitabine, Paclitaxel Albumin-Bound, and Calcium Folinate

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Region Hovedstaden

Ischaemic stroke

Not yet recruiting

A study to evaluate the use of tocilizumab in adults with acute ischemic stroke undergoing mechanical clot removal.

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Oslo University Hospital HF

Renal transplant

Not yet recruiting

Study of the effect of dapagliflozin on the development of post-transplant diabetes in kidney transplant recipients

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Odense University Hospital

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Helsingborg

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies exploring treatments for heart failure and cardiovascular conditions, including research on combination therapies to reduce cardiovascular mortality.

  • Heart Failure Prevention
  • Atrial Fibrillation
  • Takotsubo Syndrome

Groundbreaking trials evaluating novel drug combinations and therapeutic approaches for cardiac conditions.

02 Oncology Studies

Advanced research focusing on multiple myeloma treatment, particularly for patients with relapsed or refractory conditions.

  • Blood Cancer Therapies
  • Combination Treatment Approaches
  • Bladder Cancer Management

Evaluating innovative therapeutic combinations and comparing effectiveness of different treatment regimens.

03 Infectious Diseases

Clinical investigations into treatments for various infections, including bacterial infections and antibiotic resistance.

  • Staphylococcus Aureus Treatment
  • Urinary Tract Infections
  • Viral Lung Infections

Studies focusing on alternative antibiotics and novel approaches to combat resistant infections.

04 Mental Health Research

Studies examining innovative treatments for psychiatric disorders, including treatment-resistant conditions.

  • Schizophrenia Spectrum Disorders
  • Treatment-Resistant Depression
  • Novel Therapeutic Approaches

Investigating immunomodulatory treatments and new compounds for mental health conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.